



**XPRIZE
HEALTHSPAN**

R42 XPrize Healthspan Superteam Coalition

Demo Day - Aug 16, 2024

R42 XPrize Healthspan Team - Youth, Age, Brilliance!!



Otto Farag

(Palo Alto, CA), Rising junior at the University of British Columbia studying international economics



Kim Parnell

(Sunnyvale, CA) Stanford PhD Mech Engineer; Expert Witness for Litigation Patents, Failures, Product Liability; Consultant: Mech Engineer



Cate Pittman

(Woodside, CA), Rising sophomore at Dartmouth College studying engineering



Team Mentor

Dr. Ronjon Nag is an inventor and entrepreneur, and Adjunct Professor in Genetics at Stanford Medicine. He has been working in AI for 40 years.



Paul Harris

(UK, Cambridge) Bio-tech, healthspan, investing, Molecular bio Imperial



Kateryna Kostyuchenko

(Kyiv, Ukraine) Data analyst, DAO community lead, Decentralized Science advocate



Fernando Aires

(Scottsdale, AZ) - R42 LP, real estate investor, biohacker, prev: Apple chip designer, program manager IP for Apple & 3rd party vendors


XPrize is a \$101M, 7 year global competition to increase healthspan

- Winning team must give their therapeutic in 1 year or less and prove a 10 year minimum increase in lifespan
- Immune, Cognitive, and Muscle function tests are used to evaluate lifespan increase
- R42 Superteam - partnering with multiple R42 portfolio companies

Competition Milestones over 7 Years



How to Win the \$101M HealthSpan XPrize?



Muscle Function Testing .. *includes Physical & Fluid Biomarkers*

- **Endurance Capacity: Peak VO₂**
- **Lower Body Power: Rate of Torque Development**
- **Total Muscle Mass: D3 Creatine Dilution**

Function Health Test: \$500 Annual for 100+ Lab Tests

Cognitive Function Testing

- **Cognitive Summary Score: NIH Fluid Composite Score**
- **NeuroGames, blood biomarkers, genetics, and brain MRI**

Cognitive Test: from \$99 per Person

Immune Function Testing

- **Response to challenge: *Ex vivo* native immune response**
- **Immune cell composition: IMM-AGE score**
- **Inflammatory status: SASP Index**

Immune Function: \$2500-\$5000 per person


XPrize Team Advisory Board

Prof Michael Snyder
Chair, Stanford Genetics

Prof Anne Friedlander
Stanford Human Biology

Prof Lorna Harries
Exeter University, CSO of Senisca


Current Superteam Companies







Supplements to induce ketosis
without fasting or dieting

XPrize focus



Enhances **cognitive** function, supports
anaerobic exercise for **muscle** building, and
boosts mitochondrial function




keto.swiss



AGEMICA

Vaccine for aging using an Artificial Intelligence driven approach

XPrize focus



Enhances **immune** function and extends lifespan.
 Improves **muscle** function in FSHD
 (Facioscapulohumeral Muscular Dystrophy) patients,
 additionally aiming for the \$10M FSHD bonus prize



AGEMICA

Creating a vaccine for aging



Agemica's platform predicts drugs to cure dis

Agemica's platform rediscovered standards of care for 17 cancers. It also suggests combinations of the above drugs with anti-aging drug candidates to improve efficacy, reduce side effects, and reduce chances of developing drug resistance.



AGEMICA

Board of Directors-Cofounders



PROF. RONJON NAG

CEO / Co-founder

Dr. Ronjon Nag is an investor and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine and a Visiting Fellow at the Stanford Center for Language and Information (CSLI). He is the founder of the R42 Institute which invents, informs, and invests. Ronjon is a Trustee of the Institute of the Institution of Engineering and Technology (IET) - 160,000 members. He has won the 2021 IEEE SVC Outstanding Engineer award, the IET Mountbatten Medal, the \$1m Verizon Powerful Answers Award (the Bounce Imaging award he is Chairman), and the 2023 COGS (50,000 attendees AI conference) Lifetime Achievement award. He is a founder and advisor/board member and part owner of some 100 AI and Biotech start-ups. His companies have been sold to Apple, BlackBerry, and Motorola.

He has been a pioneer of smartphones and the 'app store' they depend on. He has worked on neural networks, speech search, mobile search, voice recognition, text prediction, and handwriting recognition. Currently, he works at the intersection of mathematics and medicine and teaches popular courses on AI, Genes, Ethics, Longevity Science, and Venture Capital at Stanford University and through the Stanford Continuing Studies Program (where anyone can register with no prerequisites).

PROF. RONJON NAG

DR. YASAMAN KALANTARMOTAMEDI

CTO / Co-founder

Yasaman is a Ph.D. graduate of the University of Cambridge in AI for Drug Discovery with 10 years of experience. She has an MSc degree in machine learning from University College London.


DR. YASAMAN KALANTARMOTAMEDI






Bioreactor-Grown Mitochondria transfused back into patient

XPrize focus



Increases energy throughout the body, enhancing overall biological function. All three focus areas benefit from this therapeutic approach



Mitochondrial dysfunction is implicated in dozens of age-related diseases, including Alzheimer's, retinal disease, liver dysfunction, immune senescence, and more.

Mitrix Bio has pioneered a new way of addressing these diseases, using young bioreactor-grown mitochondria encased in vesicles, which we call "Mitlets."

Our mission: prototype the components and techniques needed for a fundamental advancement in human medicine.

Bioreactor

The bioreactor grows young mitochondria in large quantities then wraps them in a special coating with receptors to target specific organs. The goal is to produce bioreactor-grown mitochondria on an industrial scale, sufficient to supplement every person over the age of 55... Learn more.

[About](#) [Science](#) [News](#) [Contact](#)



Team




Tom Benson
CEO




Kyle Cetrulo
COO



Benedict Albeni Ph.D.
Scientific Advisor



Vinit Marhajan MD, Ph.D.
CMA



George Wu MD, Ph.D.
Scientific Advisor



Eric Bollard Ph.D.
Scientific Advisor



Martin Pelletier Ph.D.
Scientific Advisor




Aida Adilmoghaddam Ph.D.
Scientific Advisor




Health metrics & biomarker tracker using multiple sensors

XPrize focus




Clinical trial partner for tracking health data, including vitals, hormonal levels, cardiovascular health, biomarkers, small molecules, and blood vessel management






Radically improves oxygen delivery using nanoparticles

XPrize focus



Improves VO₂, important for **muscle** enhancement. Potential benefits for brain health and **cognition**



Team



Prof. Jayakumar Rajadas, PhD
Co-Founder & Chief Scientist



Nikki V. Sarto
Co-Founder & CEO



Dr. Artem Trotsyuk, PhD
Chief Technical Officer




Dr. Anastassios Retzius, PhD
Director of Regulatory and Clinical Affairs

swaza.life



Targets specific senescent (zombie) cells with DNA damage

XPrize focus



Removing senescent cells enhances **immunity**. These cells stop dividing but remain alive, releasing toxins that cause chronic inflammation and fibrosis



TARGETING UNDERLYING BIOLOGICAL DRIVERS OF CHRONIC DISEASES

Rubedo discovers and develops medicines to keep you biologically young by targeting the pathologic cells that drive aging

LEADERSHIP AND FOUNDERS


The Rubedo leadership team is comprised of industry leaders from large pharma, leading biotech companies and pioneers in longevity, early development chemistry, technology, and life sciences. The team has extensive expertise in drug development across early stage to commercialization



MARCO QUARTA, PHD
Co-Founder and CEO



MARK GALLOP, PHD
Co-Founder, Chairman Chemistry and Development




OFIR MORENO, PHD
SVP Drug Discovery

rubedolife.com




Uses AI to discover drugs that prevent brain degeneration

XPrize focus



AI-driven approach to reversing brain aging enhances **cognitive** functions and combats neurodegenerative disorders like Alzheimer's

Dementia risk grows exponentially with age



Our Executive Team has a deep personal connection to fighting brain aging. Christin's grandmother passed away from Alzheimer's disease when she was a child. She witnessed the suffering that brought to her grandmother and to her loved ones. Since that time, she has had a lifelong commitment to creating better treatments for Alzheimer's, starting with reading about the hippocampus as a third grader in the school library and then going on to obtain her MD and PhD in Neuroscience from the University of Pittsburgh and Carnegie Mellon Medical Scientist Training Program. She completed her postdoctoral training at MIT and is an expert in AI and computational modeling.


Update to: Priyanka was diagnosed with early onset glaucoma in her twenties, a neurodegenerative condition that left her temporarily blind for several months during her PhD at the University of Cambridge. Getting an early diagnosis was crucial in her successful treatment. Glaucoma is age-related and still doesn't have a cure. Slowing down biological aging of the neurons in her eyes can prevent her glaucoma from progressing to irreversible blindness. Motivated by her own diagnosis, she is deeply committed to finding therapies that slow down aging and treat neurodegenerative conditions.






Mimics fasting with supplements to enhance cellular cleanup


XPrize focus



Spermidine enhances autophagy, protecting against neurodegenerative diseases. Improves **muscle** function by clearing damaged cellular components and boosts **immunity** by eliminating pathogens




mimiohealth.com





General AI support with
biomedical platform and tools

XPrize focus



Cross check and manage different
effects of various therapeutics across
our XPrize SuperTeam coalition



Adaptive Trial to Evaluate Largest Therapeutic Impact

- Adaptive trial design, creating mixed groups with different treatments so we can discover what treatments have the most impact.
- 30 to 60 days
- 10 to 20 people
- Relatively inexpensive trials used to help design and fine tune larger trials.
- Treatments that show no or very little impact after PoC trial will be dropped or replaced
- PoC trials to be run on the cheap.
 - ◆ donated meds,
 - ◆ at cost or donated tests and resources
 - ◆ Self testing and self reporting
 - ◆ Knowledge and facilities exchanged for publicity and logo added.

Final Trial Design: 1 Year Large Group Trial

→ 100-150 people from our Population:

- ◆ Average age : 75 (Age Range 50 to 80)
- ◆ Region: United States
- ◆ Health factors: above average BMI and low activity levels
- ◆ Gender ratio: close to 50%, Diverse ethnicity

→ Location:

- ◆ United states (Depending on FDA approval)

→ Duration

- ◆ 3 months of pre-trial baseline testing
- ◆ 1 year of interventions and testing

Pre-Trial At Home Baseline Testing

- Testing done in one month intervals for three months before the trials start
- Participants will be given monitoring devices to both track exercise and establish measurements for Peak VO2 max
- Cognitive and Peak VO2 tests are done remotely while test kits for immune and D3 Creatine Dilution are shipped to participants for at-home testing

Trial Intervention Design

- Randomized participant groups are given slight variations of most effective interventions in Proof of Concept Trial
- Low-carb diets, regular exercise routines implemented
- Participant adherence is tracked by smart devices
- Final 3 testing rounds are done in same way as initial rounds

XPrize Competition Guidelines - Highlights

- Interventions cannot include measures used for endpoint assessment.
- Provide federal regulatory approvals, safety monitoring plans for trials
- Team may recruit experts, add new members at any time.



TEAM LOCATIONS



XPrize Potential Trial Participants & Investors

Potential trial
participant?

[Trial contact form:](#)

<https://bit.ly/R42-xprize-trial-sub>



Sponsor our R42
XPrize Superteam?

[Sponsor contact form:](#)

<https://bit.ly/R42-xprize-sponsor>



Questions? Email us:

XPrize-R42@GoogleGroups.com